For the latest media releases and news about Pharmaxis Ltd, please select from the following articles. Material news announcements made by Pharmaxis are first filed with the Australian Securities Exchange (ASX) and are also available on the ASX website.
Pharmaxis cancer drug doubles response rate to standard therapy in blood cancer pre clinical studies
- Nature Communications publishes peer-reviewed data from highly predictive pre clinical models using cells from mylodysplastic syndrome patients
- Best in class results from Combination of PXS-5505 and standard of care demonstrates a strong rationale for treatment of several blood cancers